Water Operators Enabled to Cut CO2e Emissions by 2.8 Million Metric Tons, Using Xylem Technology
15.5.2023 14:30:00 EEST | Business Wire | Press release
Global water technology company Xylem (NYSE: XYL) delivered significant progress towards its Sustainability Goals in 2022, including enabling water utilities to reduce their CO2e emissions by 2.8 million metric tons since 2019. Through its operations, supplier and sector-wide partnerships, and green finance offerings, Xylem aims to advance water security by reducing greenhouse gas (GHG) emissions, building watershed stewardship and resilience to climate change, and advancing equitable access to Water, Sanitation and Hygiene (WASH).
The results, captured in Xylem’s latest Sustainability Report, saw the company achieve its 2025 CO2e emissions reduction goal well ahead of schedule. The reduction was enabled by the deployment of high-efficiency technologies and digital solutions. Xylem also made notable progress in reducing its own emissions, with Scope 1 and Scope 2 emissions down 21% year-on-year, while also continuing to make strides on water and waste footprint reductions across its operations.
“The stakes have never been higher in our work to tackle the world’s water challenges,” Patrick Decker, President and CEO of Xylem, said. “As impacts from climate change intensify, water operators in utilities and businesses are leaning in to be part of the solution – embracing advanced technologies that improve the resiliency and sustainability of water systems at an affordable cost – all while lowering carbon emissions.”
“Our latest Sustainability Report captures the impact of this team effort. In partnership with our customers and communities, we are working towards making the water sector a leader in climate change mitigation while solving the world’s toughest water challenges,” Decker added.
With 2022 marking another record-setting year of severe weather events, Xylem also expanded its humanitarian support. As part of the Xylem Watermark program, employees volunteered 157,000 hours to address water, sustainability, and community challenges, an increase of 39% on 2021. The program’s initiatives included providing vital aid to communities in Ukraine and to earthquake-affected regions of Turkey.
“In 2022, we were proud to partner with our customers to support their exceptional strides towards creating more modern, resilient, and environmentally sensitive water systems,” said Claudia Toussaint, Xylem’s Chief People and Sustainability Officer. “The vision of our customers and the ingenuity and diversity of our teams have been instrumental in achieving these results. It allows us to look to the future with renewed optimism and ambition.”
Other key highlights detailed in the Sustainability Report include:
- Executed a $1 billion credit facility that ties fees and interest rates to sustainability-related performance indicators, including emissions reduction.
- Reduced total process water use by 26% since 2019 and moved 12 of its 22 major facilities to 100% process water recycling and reuse.
- 88% of the electricity used at Xylem manufacturing, office, and service facilities came from renewable sources in 2022, an increase of 13% from 2021.
- Onboarded over 600 suppliers to the WASH4Work pledge and included supply partners in community WASH projects since 2019.
- Leveraged Xylem technology, solutions, and partnerships to mobilize aid for 30 areas impacted by disaster.
- Provided WASH solutions to communities in need, reaching more than 2.4 million people.
- Engaged 11,800 students through Xylem Ignite, the company’s youth program, with events including the Global Student Innovation Challenge, regional hackathons, and a six-month Innovation Incubator.
To learn more about Xylem’s sustainability progress, download the 2022 Sustainability Report.
*Refers to cars powered by internal combustion engine.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005421/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
